Abu Dhabi-based Arcera Life Sciences will pay more than $1 billion in total potential value to license Innogen’s China-approved GLP-1 therapy efsubaglutide alfa for Africa, Eastern Europe, Latin America and the Middle East, the companies said Thursday.
Arcera will make an initial $38 million in near-term milestone payments, including a $15 million upfront, non-refundable payout. Innogen will receive a double-digit royalty percentage on net sales plus additional revenue-based milestones.
Under the agreement, Arcera gains exclusive development and commercialization rights in its priority markets, while Innogen retains rights for the rest of the world. Founded in 2024, Arcera specializes in generics, established medicines and licensing innovative therapies beyond saturated Western markets.
“Cardiometabolic diseases remain among the most pressing healthcare challenges in the markets we serve,” Isabel Afonso, chief executive officer of Arcera Life Sciences, said in a statement.
In mainland China, efsubaglutide alfa is already approved to treat type 2 diabetes and is under study as a weight-loss treatment. Late-stage data showed that when added to metformin, the drug reduced patients’ HbA1c by 1.8% at 24 weeks, compared with a 0.74% reduction on placebo.
In Chinese adults with obesity, 18 weeks of weekly treatment reduced body weight by 10.6% and increased muscle-to-fat ratio by 45.3%, while liver fat content fell by more than 50%, according to the companies’ release.
“We are delighted to establish this collaboration with Arcera, which represents an important step in Innogen’s international expansion,” Qinghua Wang, M.D., Ph.D., founder, chairman and chief executive officer of Innogen, said in a statement.
“By combining Innogen’s scientific innovation with Arcera’s strengths in international regulatory affairs and commercialization, we aim to broaden access to differentiated therapies and ultimately improve the quality of life of patients around the world,” he added.
Established in 2024 by ADQ, an Abu Dhabi-based sovereign investor, Arcera Life Sciences develops, manufactures and commercializes more than 2,000 medicines across over 100 markets, supported by manufacturing and packaging facilities in eight countries. The company focuses on generics, established medicines and licensing innovative therapies beyond saturated Western markets, and its portfolio includes Amoun in Egypt.
The deal arrives as competition intensifies in China. Last week, GLP-1 drugs from Pfizer and Innovent Biologics were added to China’s 2027 drug reimbursement list for type 2 diabetes alongside existing options from Novo Nordisk, Eli Lilly and Innogen. Lilly’s oral weight-loss drug Foundayo was also approved in China, beating Novo Nordisk’s Wegovy pill to market.